497 related articles for article (PubMed ID: 29472720)
1. CAR T-cells targeting FLT3 have potent activity against FLT3
Jetani H; Garcia-Cadenas I; Nerreter T; Thomas S; Rydzek J; Meijide JB; Bonig H; Herr W; Sierra J; Einsele H; Hudecek M
Leukemia; 2018 May; 32(5):1168-1179. PubMed ID: 29472720
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
[TBL] [Abstract][Full Text] [Related]
3. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
[TBL] [Abstract][Full Text] [Related]
4. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells.
Wang Y; Xu Y; Li S; Liu J; Xing Y; Xing H; Tian Z; Tang K; Rao Q; Wang M; Wang J
J Hematol Oncol; 2018 May; 11(1):60. PubMed ID: 29716633
[TBL] [Abstract][Full Text] [Related]
5. Leukemogenic potency of the novel FLT3-N676K mutant.
Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
[TBL] [Abstract][Full Text] [Related]
6. Wu-5, a novel USP10 inhibitor, enhances crenolanib-induced FLT3-ITD-positive AML cell death via inhibiting FLT3 and AMPK pathways.
Yu M; Fang ZX; Wang WW; Zhang Y; Bu ZL; Liu M; Xiao XH; Zhang ZL; Zhang XM; Cao Y; Wang YY; Lei H; Xu HZ; Wu YZ; Liu W; Wu YL
Acta Pharmacol Sin; 2021 Apr; 42(4):604-612. PubMed ID: 32694757
[TBL] [Abstract][Full Text] [Related]
7. Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML.
Dany M; Gencer S; Nganga R; Thomas RJ; Oleinik N; Baron KD; Szulc ZM; Ruvolo P; Kornblau S; Andreeff M; Ogretmen B
Blood; 2016 Oct; 128(15):1944-1958. PubMed ID: 27540013
[TBL] [Abstract][Full Text] [Related]
8. CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations.
Tang L; Huang H; Tang Y; Li Q; Wang J; Li D; Zhong Z; Zou P; You Y; Cao Y; Kong Y; Guo A; Zhou S; Li H; Meng F; Xiao Y; Zhu X
Clin Transl Med; 2022 Sep; 12(9):e1043. PubMed ID: 36163632
[TBL] [Abstract][Full Text] [Related]
9. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
10. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
[TBL] [Abstract][Full Text] [Related]
11. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
[TBL] [Abstract][Full Text] [Related]
12. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
[TBL] [Abstract][Full Text] [Related]
13. Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.
Hirade T; Abe M; Onishi C; Taketani T; Yamaguchi S; Fukuda S
Int J Hematol; 2016 Jan; 103(1):95-106. PubMed ID: 26590920
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib and navitoclax act synergistically to target NUP98-NSD1
Kivioja JL; Thanasopoulou A; Kumar A; Kontro M; Yadav B; Majumder MM; Javarappa KK; Eldfors S; Schwaller J; Porkka K; Heckman CA
Leukemia; 2019 Jun; 33(6):1360-1372. PubMed ID: 30568173
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
[TBL] [Abstract][Full Text] [Related]
16. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
[TBL] [Abstract][Full Text] [Related]
17. NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A
Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Mathew NR; Baumgartner F; Braun L; O'Sullivan D; Thomas S; Waterhouse M; Müller TA; Hanke K; Taromi S; Apostolova P; Illert AL; Melchinger W; Duquesne S; Schmitt-Graeff A; Osswald L; Yan KL; Weber A; Tugues S; Spath S; Pfeifer D; Follo M; Claus R; Lübbert M; Rummelt C; Bertz H; Wäsch R; Haag J; Schmidts A; Schultheiss M; Bettinger D; Thimme R; Ullrich E; Tanriver Y; Vuong GL; Arnold R; Hemmati P; Wolf D; Ditschkowski M; Jilg C; Wilhelm K; Leiber C; Gerull S; Halter J; Lengerke C; Pabst T; Schroeder T; Kobbe G; Rösler W; Doostkam S; Meckel S; Stabla K; Metzelder SK; Halbach S; Brummer T; Hu Z; Dengjel J; Hackanson B; Schmid C; Holtick U; Scheid C; Spyridonidis A; Stölzel F; Ordemann R; Müller LP; Sicre-de-Fontbrune F; Ihorst G; Kuball J; Ehlert JE; Feger D; Wagner EM; Cahn JY; Schnell J; Kuchenbauer F; Bunjes D; Chakraverty R; Richardson S; Gill S; Kröger N; Ayuk F; Vago L; Ciceri F; Müller AM; Kondo T; Teshima T; Klaeger S; Kuster B; Kim DDH; Weisdorf D; van der Velden W; Dörfel D; Bethge W; Hilgendorf I; Hochhaus A; Andrieux G; Börries M; Busch H; Magenau J; Reddy P; Labopin M; Antin JH; Henden AS; Hill GR; Kennedy GA; Bar M; Sarma A; McLornan D; Mufti G; Oran B; Rezvani K; Shah O; Negrin RS; Nagler A; Prinz M; Burchert A; Neubauer A; Beelen D; Mackensen A; von Bubnoff N; Herr W; Becher B; Socié G; Caligiuri MA; Ruggiero E; Bonini C; Häcker G; Duyster J; Finke J; Pearce E; Blazar BR; Zeiser R
Nat Med; 2018 Mar; 24(3):282-291. PubMed ID: 29431743
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3.
Lin PH; Lin CC; Yang HI; Li LY; Bai LY; Chiu CF; Liao YM; Lin CY; Hsieh CY; Lin CY; Ho CM; Yang SF; Peng CT; Tsai FJ; Yeh SP
Leuk Res; 2013 Mar; 37(3):287-92. PubMed ID: 23276395
[TBL] [Abstract][Full Text] [Related]
20. Emergence of crenolanib for FLT3-mutant AML.
Fathi AT
Blood; 2013 Nov; 122(22):3547-8. PubMed ID: 24263951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
